JP2019534258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534258A5 JP2019534258A5 JP2019518292A JP2019518292A JP2019534258A5 JP 2019534258 A5 JP2019534258 A5 JP 2019534258A5 JP 2019518292 A JP2019518292 A JP 2019518292A JP 2019518292 A JP2019518292 A JP 2019518292A JP 2019534258 A5 JP2019534258 A5 JP 2019534258A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- particles
- exosomes
- combination
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 claims description 62
- 239000002245 particle Substances 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 210000001808 exosome Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 102000003812 Interleukin-15 Human genes 0.000 claims description 22
- 238000011319 anticancer therapy Methods 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 11
- 108010074708 B7-H1 Antigen Proteins 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023025895A JP2023078140A (ja) | 2016-10-05 | 2023-02-22 | Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404520P | 2016-10-05 | 2016-10-05 | |
| US62/404,520 | 2016-10-05 | ||
| PCT/US2017/055352 WO2018067825A1 (en) | 2016-10-05 | 2017-10-05 | Methods and compositions related to nk cell and anti-pdl1 cancer therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023025895A Division JP2023078140A (ja) | 2016-10-05 | 2023-02-22 | Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534258A JP2019534258A (ja) | 2019-11-28 |
| JP2019534258A5 true JP2019534258A5 (OSRAM) | 2021-05-20 |
| JP7239179B2 JP7239179B2 (ja) | 2023-03-14 |
Family
ID=61831979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518292A Active JP7239179B2 (ja) | 2016-10-05 | 2017-10-05 | Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 |
| JP2023025895A Pending JP2023078140A (ja) | 2016-10-05 | 2023-02-22 | Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023025895A Pending JP2023078140A (ja) | 2016-10-05 | 2023-02-22 | Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190309070A1 (OSRAM) |
| EP (1) | EP3523416B1 (OSRAM) |
| JP (2) | JP7239179B2 (OSRAM) |
| KR (2) | KR102650803B1 (OSRAM) |
| CN (2) | CN118453850A (OSRAM) |
| AU (2) | AU2017340633B2 (OSRAM) |
| CA (1) | CA3039532A1 (OSRAM) |
| DK (1) | DK3523416T3 (OSRAM) |
| ES (1) | ES3014658T3 (OSRAM) |
| SG (1) | SG11201903032SA (OSRAM) |
| WO (1) | WO2018067825A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
| CA3098471C (en) * | 2018-05-22 | 2023-04-18 | Nantkwest, Inc. | Optimization of nk-92 cell growth using poloxamer |
| CN109939127A (zh) * | 2018-06-13 | 2019-06-28 | 阿思科力(苏州)生物科技有限公司 | Nk细胞的应用及包括该nk细胞的药物组合物及其应用 |
| AU2019328575B2 (en) * | 2018-08-30 | 2024-07-11 | Immunitybio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| CA3108949A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
| BR112021009485A2 (pt) * | 2018-11-15 | 2021-08-10 | Torque Therapeutics, Inc. | métodos e composições para imunoterapia de câncer |
| CN109652504B (zh) * | 2018-12-27 | 2021-03-16 | 杭州迪相实业有限公司 | 一种同时检测外泌体膜蛋白和mRNA的方法 |
| CN110205296B (zh) * | 2019-01-29 | 2021-08-24 | 上海鑫湾生物科技有限公司 | 具有Fc突变体的抗体与效应细胞的组合、用途和制法 |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| WO2021163369A2 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| JP2023024168A (ja) * | 2021-08-06 | 2023-02-16 | 国立大学法人 長崎大学 | がんの治療剤 |
| JP2024540347A (ja) * | 2021-11-09 | 2024-10-31 | ウーゲン，インコーポレイテッド | 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法 |
| WO2023247324A1 (en) * | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| WO2024108058A2 (en) * | 2022-11-18 | 2024-05-23 | Nkmax Co., Ltd. | Methods of inducing pd-l1 expression |
| WO2025010297A1 (en) * | 2023-07-05 | 2025-01-09 | Immunitybio, Inc. | Ex vivo generation of immune effector cells from apheresis material intermediates |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (OSRAM) | 1968-10-17 | 1970-08-24 | ||
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| FR2765243B1 (fr) | 1997-06-30 | 1999-07-30 | Usinor | Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction |
| CN111420032A (zh) * | 2012-03-29 | 2020-07-17 | 阿尔托生物科学有限公司 | 用于治疗肿瘤的方法 |
| DK3578201T3 (da) * | 2012-06-28 | 2023-05-08 | Univ Of Central Florida Research Foundation Incorporated | Fremgangsmåder og sammensætninger til naturlige dræberceller |
| NZ630790A (en) * | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| SG11201703397UA (en) * | 2014-10-27 | 2017-05-30 | Univ Central Florida Res Found | Methods and compositions for natural killer cells |
| ES2926673T3 (es) * | 2014-11-20 | 2022-10-27 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1 |
| US11248058B2 (en) | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| WO2016149201A2 (en) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
-
2017
- 2017-10-05 CA CA3039532A patent/CA3039532A1/en active Pending
- 2017-10-05 EP EP17859189.7A patent/EP3523416B1/en active Active
- 2017-10-05 JP JP2019518292A patent/JP7239179B2/ja active Active
- 2017-10-05 US US16/339,781 patent/US20190309070A1/en not_active Abandoned
- 2017-10-05 WO PCT/US2017/055352 patent/WO2018067825A1/en not_active Ceased
- 2017-10-05 KR KR1020197012752A patent/KR102650803B1/ko active Active
- 2017-10-05 ES ES17859189T patent/ES3014658T3/es active Active
- 2017-10-05 KR KR1020247009187A patent/KR20240042177A/ko active Pending
- 2017-10-05 SG SG11201903032SA patent/SG11201903032SA/en unknown
- 2017-10-05 AU AU2017340633A patent/AU2017340633B2/en active Active
- 2017-10-05 CN CN202410266765.3A patent/CN118453850A/zh active Pending
- 2017-10-05 DK DK17859189.7T patent/DK3523416T3/da active
- 2017-10-05 CN CN201780069203.8A patent/CN109952369B/zh active Active
-
2023
- 2023-02-22 JP JP2023025895A patent/JP2023078140A/ja active Pending
-
2024
- 2024-04-11 AU AU2024202350A patent/AU2024202350A1/en active Pending
-
2025
- 2025-01-06 US US19/011,349 patent/US20250136698A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534258A5 (OSRAM) | ||
| Taefehshokr et al. | Promising approaches in cancer immunotherapy | |
| Maiorino et al. | Innate immunity and cancer pathophysiology | |
| Awad et al. | Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression | |
| Chen et al. | CD4+ CD25+ regulatory T cells in tumor immunity | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Chmielewski et al. | CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer | |
| US9561291B2 (en) | Methods of targeting T-cells to tumors | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| Kennedy et al. | Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer | |
| Schijns et al. | First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo-and auto-immune tumor reactivity | |
| US20250114391A1 (en) | Beta-glucan methods and compositions that affect the tumor microenvironment | |
| Goldberg et al. | Enhancing cancer immunotherapy via activation of innate immunity | |
| JP2019534258A (ja) | Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物 | |
| JP2016540042A5 (OSRAM) | ||
| Rusch et al. | Immunotherapy as an option for cancer treatment | |
| US20230172967A1 (en) | Beta-glucan immunotherapies affecting the immune microenvironment | |
| JP2017524737A (ja) | 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン | |
| Huber et al. | Immmunotherapy of cancer: from vision to standard clinical practice | |
| Shallis et al. | The multi-faceted potential of CD38 antibody targeting in multiple myeloma | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| WO2018210223A1 (zh) | 针对tim-3的抗体分子、抗原结合片段及其医药用途 | |
| Cox et al. | Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma | |
| Huang et al. | Cellular and antibody based approaches for pediatric cancer immunotherapy | |
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 |